Cell and Gene Therapy
The cell and gene therapy market is rapidly evolving, presenting new challenges for stakeholders and shifting traditional policy and access paradigms. Our cell and gene experts help stakeholders navigate the landscape through data-driven, end-to-end life cycle support to advance key commercialization and patient access goals.
Advancements in Cell Therapies Require New Patient Support Solutions
Manufacturers seeking Food & Drug Administration (FDA) approval for cell therapies will need to assess the financial and logistical burden on patients and develop novel solutions to help alleviate these challenges.
Interview: Data Deep Dive: CAR T-Cell Therapy for Large B-Cell Lymphoma
Tune into our first episode in the Avalere Health Essential Voice podcast series focused on disease education. In this segment, our experts discuss recent research that, using Medicare fee-for-service claims data, studied healthcare utilization, costs, outcomes, and other characteristics of patients who received CAR T-cell therapy for large B-cell lymphoma.
Video: Data Deep Dive: CAR T-Cell Therapy for Large B-Cell Lymphoma
Tune into our first episode in the Avalere Health Essential Voice series focused on disease education. In this segment, our experts discuss recent research that, using Medicare fee-for-service claims data, studied healthcare utilization, costs, outcomes, and other characteristics of patients who received CAR T-cell therapy for large B-cell lymphoma.
Cell and Gene Therapy Pipeline Patient Affordability Opportunities
With a number of cell and gene therapies (CGTs) expected to obtain Food & Drug Administration (FDA) approval in the next 3 years, stakeholders must consider the unique patient access and affordability barriers that may limit patient ability to receive these novel treatments. Stakeholders should explore affordability solutions that can optimize access, or they risk excluding patients from obtaining potentially life-saving treatments.
Medicaid Programs Seek New Approaches for Cell and Gene Therapies
State Medicaid programs are likely to face significant budget impacts from emerging cell and gene therapies and may seek to implement a variety of strategies to manage utilization and address provider reimbursement and financing challenges.
CMS Finalizes New Reimbursement Method for CAR-T Treatments
Policy changes to Medicare’s CAR-T inpatient reimbursement set a precedent for high-cost durable treatments. Looking ahead, questions and concerns remain for pipeline cell and gene therapies that have high up-front costs.
With an Influx of Cell and Gene Therapies on the Horizon, New Access, Coverage, and Financing Models Are Needed
With new cell and gene therapies poised to revolutionize treatment for a growing number of disease states, stakeholders are working to reimagine existing value and reimbursement models to meet the special challenges these breakthrough services present.
Avalere Presents First Real-World Evidence on Medicare Patients’ CAR-T Experiences at ASH Press Briefing
On Saturday, December 7, Karl Kilgore discussed “Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A First Real-World Look at Patient Characteristics, Healthcare Utilization and Costs” during a press briefing at the American Society of Hematology’s Annual Meeting.